Antithrombotic regimens in patients with atrial fibrillation and coronary disease: optimizing efficacy and safety.


Clear evidence supports the value of oral anticoagulation (OAC) with vitamin K antagonists in preventing stroke and thromboembolism in patients with atrial fibrillation (AF) who have well-established risk factors. For this indication, vitamin K antagonists have been shown to be superior to single or dual antiplatelet agents in reducing thromboembolic… (More)
DOI: 10.1016/j.jacc.2013.04.072